Top Page
Impedimed Limited
(Sydney:IPD)
Impedimed Limited (IPD) vs. iShares MSCI Australia ETF (EWA)
Impedimed Limited Business Overview & Revenue Model
Impedimed Limited Earnings Call Summary
Impedimed Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.54M | 12.72M | 10.32M | 11.34M | 10.57M | 8.41M |
| Gross Profit | 10.14M | 10.97M | 9.01M | -13.65M | -13.35M | -12.20M |
| EBITDA | -21.08M | -17.55M | -22.05M | -20.49M | -18.65M | -20.70M |
| Net Income | -21.22M | -23.24M | -19.79M | -20.52M | -19.87M | -20.71M |
Balance Sheet | ||||||
| Total Assets | 39.19M | 41.66M | 46.99M | 68.74M | 58.70M | 34.20M |
| Cash, Cash Equivalents and Short-Term Investments | 17.69M | 22.18M | 24.63M | 45.71M | 40.73M | 19.68M |
| Total Debt | 1.05M | 14.49M | 1.14M | 1.45M | 170.00K | 474.00K |
| Total Liabilities | 6.87M | 21.16M | 6.24M | 7.86M | 7.66M | 8.69M |
| Stockholders Equity | 32.32M | 20.50M | 40.74M | 60.88M | 51.04M | 25.51M |
Cash Flow | ||||||
| Free Cash Flow | -19.72M | -15.63M | -20.89M | -24.09M | -20.89M | -15.71M |
| Operating Cash Flow | -18.29M | -14.64M | -17.79M | -18.05M | -15.66M | -13.26M |
| Investing Cash Flow | -2.02M | -989.00K | -3.10M | -6.04M | -5.22M | -2.46M |
| Financing Cash Flow | -462.00K | 13.64M | -481.00K | 27.93M | 39.92M | 16.47M |
Impedimed Limited Technical Analysis
Impedimed Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | AU$64.39M | -48.55 | -6.35% | ― | 2.23% | -263.16% | |
| ― | AU$70.12M | ― | -128.19% | ― | -14.25% | -22.83% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | AU$45.57M | ― | -44.16% | ― | 25.47% | 14.08% | |
| ― | $79.41M | ― | -74.00% | ― | 23.31% | -17.35% | |
| ― | AU$170.03M | -16.13 | -70.55% | ― | ― | -257.32% | |
| ― | AU$81.13M | ― | -31.98% | ― | 34.20% | -23.90% |
Impedimed Limited Corporate Events
Impedimed Limited’s recent earnings call conveyed a mixed sentiment, highlighting both significant achievements and notable challenges. The company celebrated advancements in reimbursement coverage and revenue growth, yet faced hurdles in U.S. sales, cash flow issues, and adverse effects from currency fluctuations.
ImpediMed Limited, a medical technology company specializing in bioimpedance spectroscopy, offers innovative solutions for patient health management, particularly in lymphoedema, heart failure, and body composition. The company’s latest quarterly report reveals a record revenue of A$3.6 million, driven by strong demand for its SOZO Digital Health Platform. Despite a decrease in Total Contracted Value compared to the previous quarter, the company achieved an Annual Recurring Revenue of A$14.4 million, highlighting its resilience amid currency fluctuations. ImpediMed’s strategic initiatives include the launch of SOZO Pro, enhancing its market position and expanding its reach in the US healthcare sector. The company maintains a robust cash balance of A$23.0 million, ensuring continued investment in growth opportunities. Looking ahead, ImpediMed remains focused on expanding its market presence and achieving cash flow break-even, supported by its innovative product offerings and strategic partnerships.
ImpediMed Limited has released an investor presentation detailing its Q1 FY26 results, which will be delivered to investors and analysts. This announcement is part of the company’s ongoing efforts to maintain transparency with stakeholders and provide insights into its financial performance and strategic direction.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
ImpediMed Limited reported a record revenue of A$3.6 million for the first quarter of FY26, despite challenges such as a stronger Australian dollar and delays in hospital approvals. The company is expanding its market presence with over 600 SOZO units installed in leading US hospitals and new system agreements providing access to over 700 hospitals. The launch of SOZO Pro, the only FDA-cleared BIS device for patients with cardiac implantable devices, is expected to drive scalable growth. Despite a decrease in Total Contracted Value compared to the previous quarter, the company saw a 9% revenue increase and maintained a low churn rate, indicating strong market demand and customer retention.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
ImpediMed Limited has announced the upcoming release of its Q1 FY26 Quarterly Cash Flow Report and the launch of the ImpediMed Investor Hub. The Investor Hub is designed to improve communication and engagement with investors by providing a centralized platform for accessing company updates, ASX announcements, and strategic insights. This initiative aims to offer investors a deeper understanding of ImpediMed’s products and growth opportunities, potentially enhancing stakeholder engagement and market positioning.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
ImpediMed Limited announced a correction to its 2025 Remuneration Report, clarifying that the Board Chair’s fee will be paid 85% in cash and 15% in equity, aligning with the payment structure for other Non-executive Directors. This adjustment reflects the company’s commitment to transparency and consistency in its remuneration practices, which may impact stakeholder perceptions and corporate governance standards.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
ImpediMed Limited has announced the details for its upcoming Annual General Meeting, which will be held online on November 18, 2025. The company has provided an online meeting guide to assist shareholders in attending and voting during the meeting, emphasizing the need for compatible browsers and necessary identification information.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
Impedimed Limited announced the cessation of certain securities, specifically the lapse of 1,181,000 options and 7,556,058 performance rights due to unmet conditions. This announcement may impact the company’s financial structure and could influence investor perceptions regarding the company’s operational and strategic execution.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
Impedimed Limited announced the issuance of 17,250,000 unquoted equity securities under an employee incentive scheme, which are not intended to be quoted on the ASX. This move could potentially strengthen the company’s employee engagement and retention strategies, while also impacting its financial structure and market positioning.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
ImpediMed Limited announced that a major US health insurer has issued positive coverage for bioimpedance spectroscopy (BIS) under CPT Code 93702, recognizing it as medically necessary for lymphedema assessment. This development significantly expands insurance coverage for ImpediMed’s SOZO® Digital Health Platform, now covering over 301 million lives and 86% of the US population. The decision is expected to enhance the commercial viability of SOZO, allowing for earlier detection and better management of lymphedema, thus improving the quality of life for breast cancer survivors. This expanded coverage is a crucial step towards proactive health management and aligns with the insurer’s mission to provide high-quality care.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.14 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
ImpediMed Limited is a global medical technology company specializing in bioimpedance spectroscopy (BIS) technology for non-invasive clinical assessment and monitoring of fluid status and tissue composition, primarily targeting secondary lymphoedema in breast cancer patients. In its 2025 financial year, ImpediMed reported a 23% revenue growth, driven by increased sales of its SOZO® Digital Health Platform and expanded reimbursement coverage. The company also made strategic advancements, including a successful trial in heart failure applications and the introduction of SOZO Pro for broader clinical settings. Key financial highlights include a total revenue of $12.7 million, a 25% increase in SOZO-Core business revenue, and a reduction in operating cash expenditure by 16%. Looking forward, ImpediMed aims to accelerate revenue growth, expand reimbursement coverage, and achieve profitability through continued focus on sales execution and innovation.
ImpediMed Limited has announced that its 2025 Annual General Meeting will be held on November 18, 2025. The company is also accepting nominations for director positions, with a deadline for submissions set for September 26, 2025. This announcement is significant for stakeholders as it outlines key governance activities and timelines, potentially impacting the company’s strategic direction and leadership.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.14 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
Impedimed Limited has announced the quotation of 6,281,809 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of the company’s strategy to enhance its capital structure and potentially increase its market presence. The release of these securities, previously issued under an employee incentive scheme, signifies a step towards greater liquidity and flexibility in the company’s financial operations, which could positively impact its stakeholders and market positioning.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.14 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
ImpediMed Limited has released its Annual Report for the financial year ending 30 June 2025. This announcement marks a significant step in the company’s ongoing efforts to enhance transparency and communication with its stakeholders, potentially impacting its market positioning and stakeholder relations positively.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.12 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
ImpediMed Limited has released its preliminary final report for the financial year ending June 30, 2025, showing a 23% increase in revenue to $12.7 million. Despite this growth, the company reported a 17% increase in losses, amounting to $23.2 million, and did not declare any dividends. The report highlights a decrease in net tangible assets per security from 1.22 cents to 0.37 cents, indicating potential challenges in financial stability. These results may impact the company’s market positioning and stakeholder confidence as it continues to navigate the competitive medical technology landscape.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.12 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
ImpediMed Limited announced a change in the director’s interest, with Mr. Andrew Grant acquiring 268,169 ordinary shares, increasing his total to 2,774,399 shares. This acquisition was made through the issuance of shares in lieu of 30% of director fees for the quarter ended June 30, 2025, reflecting a strategic decision to align director compensation with company performance.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
ImpediMed Limited announced a change in the director’s interest notice, involving Ms. Christine Emmanuel-Donnelly. The change reflects the issuance of 474,084 ordinary shares to IDEAHL Pty Ltd, a trust where Ms. Emmanuel-Donnelly is a director and beneficiary, as part of her director fees for the quarter ended June 30, 2025. This move indicates a strategic decision to compensate directors through equity, potentially aligning their interests with those of shareholders and impacting the company’s financial structure.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
ImpediMed Limited announced a change in the director’s interest notice, specifically involving Ms. Janelle Delaney. The change reflects the acquisition of 268,169 ordinary shares as part of a compensation arrangement, where shares were issued in lieu of 30% of director fees for the quarter ending June 30, 2025. This adjustment in shareholding could impact the company’s governance and stakeholder interests, as it aligns director compensation with company performance.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
Impedimed Limited announced a change in the director’s interest, as Fiona Bones acquired an additional 268,169 ordinary shares, increasing her total holdings to 1,774,399 shares. This acquisition was part of a compensation arrangement where shares were issued in lieu of 30% of her director fees for the quarter ended June 30, 2025, reflecting a strategic approach to align management interests with shareholder value.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.15 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
Impedimed Limited has announced the issuance of 1,100,901 fully paid ordinary shares to its executives as part of their remuneration for the quarter ending June 30, 2025. This move, under the Executive Share Plan, reflects the company’s strategy to align executive compensation with company performance, potentially impacting its financial structure and stakeholder interests.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
Impedimed Limited announced the issuance of 1,278,591 ordinary fully paid shares to non-executive directors as part of their Non-Executive Director Share Plan, covering 30% of director fees for the quarter ending June 30, 2025. This move is part of the company’s ongoing strategy to align the interests of its directors with those of its shareholders, potentially enhancing governance and stakeholder confidence.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.